Brokerages Expect Endo International PLC (ENDP) Will Post Quarterly Sales of $690.66 Million

Analysts predict that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will announce $690.66 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Endo International’s earnings. The highest sales estimate is $732.10 million and the lowest is $660.80 million. Endo International posted sales of $700.53 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.4%. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Endo International will report full year sales of $2.84 billion for the current financial year, with estimates ranging from $2.80 billion to $2.87 billion. For the next fiscal year, analysts anticipate that the company will report sales of $2.91 billion, with estimates ranging from $2.67 billion to $3.14 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, February 28th. The company reported $0.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.16. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. During the same quarter in the previous year, the business earned $0.77 earnings per share.

Several research analysts recently commented on the stock. ValuEngine upgraded shares of Endo International from a “sell” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity set a $17.00 price target on shares of Endo International and gave the stock a “buy” rating in a research report on Friday, March 8th. BidaskClub lowered shares of Endo International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. Svb Leerink lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Finally, Leerink Swann lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Fourteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $16.00.

Several institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank bought a new position in Endo International during the 4th quarter worth approximately $21,218,000. Nordea Investment Management AB raised its holdings in Endo International by 23.0% during the 4th quarter. Nordea Investment Management AB now owns 129,200 shares of the company’s stock worth $943,000 after purchasing an additional 24,200 shares during the last quarter. Globeflex Capital L P raised its holdings in Endo International by 2.6% during the 4th quarter. Globeflex Capital L P now owns 214,135 shares of the company’s stock worth $1,563,000 after purchasing an additional 5,391 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new position in Endo International during the 4th quarter worth approximately $421,000. Finally, LMR Partners LLP bought a new position in Endo International during the 4th quarter worth approximately $442,000. 98.25% of the stock is currently owned by institutional investors.

ENDP traded up $0.01 during trading hours on Tuesday, hitting $8.42. 1,488,832 shares of the company’s stock were exchanged, compared to its average volume of 3,429,484. Endo International has a 1-year low of $5.27 and a 1-year high of $18.50. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 2.91 and a beta of 1.21.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Read More: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.